{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_references_citation in Reference Text / Citation (approximate match)
Status:
US Approved Rx
(2008)
Source:
BLA125249
(2008)
Source URL:
First approved in 2008
Source:
BLA125249
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
Source:
BLA125291
(2010)
Source URL:
First approved in 2006
Source:
BLA125141
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA103979
(2003)
Source URL:
First approved in 2003
Source:
BLA103979
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103795
(1998)
Source URL:
First approved in 1998
Source:
BLA103795
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02614833: Phase 2 Interventional Completed Adenocarcinoma Breast Stage IV
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exidavnemab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02754076: Phase 1/Phase 2 Interventional Completed MPS III B
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02384538: Phase 2 Interventional Completed Erosive Hand Osteoarthritis
(2015)
Source URL:
Class:
PROTEIN
